Cited by

• The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.

  Yang CX, Pan YX, Ye F, Zhu XD, Xue J, Li X, Yuan ZG, Zhang L, Xu L, Chen YJ, Wang NY, Sun HC, Liu XF; China Liver Cancer Study Group Young Investigators (CLEAP). Yang CX, et al. Front Immunol. 2024 Apr 22;15:1310239. doi: 10.3389/fimmu.2024.1310239. eCollection 2024. Front Immunol. 2024. PMID: 38711515 Free PMC article.
• Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.

  Li Y, Wang P, Xu J, Shi X, Yin T, Teng F. Li Y, et al. Oncoimmunology. 2024 Feb 7;13(1):2312628. doi: 10.1080/2162402X.2024.2312628. eCollection 2024. Oncoimmunology. 2024. PMID: 38343749 Free PMC article.
• Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia.

  Mishra R, Sukhbaatar A, Mori S, Kodama T. Mishra R, et al. J Exp Clin Cancer Res. 2023 Jun 1;42(1):132. doi: 10.1186/s13046-023-02645-w. J Exp Clin Cancer Res. 2023. PMID: 37259163 Free PMC article.
• Exploring the Molecular Players behind the Potentiation of Chemotherapy Effects by Durvalumab in Lung Adenocarcinoma Cell Lines.

  Saar M, Jaal J, Meltsov A, Laasfeld T, Lust H, Kasvandik S, Lavogina D. Saar M, et al. Pharmaceutics. 2023 May 12;15(5):1485. doi: 10.3390/pharmaceutics15051485. Pharmaceutics. 2023. PMID: 37242727 Free PMC article.
• Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.

  Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I, Goutam S, Navani V, Heng DYC, Cheung WY, Morris DG, Pabani A. Meyers DE, et al. JTO Clin Res Rep. 2023 Feb 24;4(4):100482. doi: 10.1016/j.jtocrr.2023.100482. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37090101 Free PMC article.